摘要
目的分析研究格列美脲与沙格列汀在二甲双胍继发失效的2型糖尿病患者当中的临床治疗效果。方法选取2013年2月—2015年2月采取二甲双胍治疗而血糖仍然没有达到标准的2型糖尿病患者108例,随机分为研究组、对照组,每组各54例,对照组对患者采取格列美脲进行治疗,研究组对患者采取沙格列汀进行治疗,研究组与对照组达到最大剂量以后,如果血糖仍然没有达标则联合应用阿卡波糖片。对研究组与对照组患者的治疗前、治疗12周后、治疗24周后的空腹血糖、餐后2小时血糖、糖化血红蛋白、体质量变化、低血糖发生率以及TG(三酰甘油)、TC(总胆固醇)、LDL-C以及HDL-C对比分析。结果临床治疗以后,研究组与对照组患者的血糖控制情况明显优于治疗前,研究组患者的空腹血糖、餐后2小时血糖以及体质量控制情况显著优于对照组(P<0.05);研究组患者低血糖发生率显著低于对照组(P<0.05);研究组患者Hb A1c达标率明显优于对照组(P<0.05)。结论对口服盐酸二甲双胍继发失效的2型糖尿病患者,联合采取沙格列汀的治疗效果明显要比联合格列美脲的效果更加明显,其Hb A1c达标率更高,发生低血糖的几率明显减少,并可以有效控制患者体质量,具有临床推广价值。
Objective To analyze the clinical effect of treating type 2 diabetes mellitus patients with metformin secondary failure with saxagliptin to glimepiride. Methods From Feb. 2013 to Feb. 2015,108 cases of type 2 diabetes mellitus patients with metformin secondary failure were chosen and divided randomly into study group and controlled group with 54 cases in each group. The controlled group was treated with glimepiride,the study group was treated with saxagliptin. If patients were treated with maximal dose with blood glucose falling below,they can be treated with acarbose. Compared the FBG,2 h PBG,BMI,Hb A1 c,incidence of hypoglycemia,TG,TC,LDL-C and HDL-C before treating and after 12 weeks,48 weeks. Results The FBG,2 h PBG,BMI of study group were better than controlled group（ P 〈0. 05）. The incidence of hypoglycemia of study group was lower than controlled group（ P 〈0. 05）. The controlling rate of Hb A1 c of study group was better than contrlled group（ P 〈0. 05）. Conclusion The clinical effect of treating type 2 diabetes mellitus patients with metformin secondary failure with saxagliptin was better than glimepiride with higher glucose-target-rate,with less incidence of hypoglycemia and effective controlling BMI to extend in clinical.
出处
《中华全科医学》
2015年第8期1280-1282,共3页
Chinese Journal of General Practice
关键词
2型糖尿病
格列美脲
沙格列汀
二甲双胍
继发失效
type 2 diabetes mellitus
Glimepiride
Saxagliptin
Metformin
Secondary failure
